Your browser doesn't support javascript.
loading
Biennial versus annual treatment for schistosomiasis and its impact on liver morbidity.
Olveda, David U; Inobaya, Marianette T; McManus, Donald P; Olveda, Remigio M; Vinluan, Marilyn L; Ng, Shu-Kay; Harn, Donald A; Li, Yuesheng; Guevarra, Jerric R; Lam, Alfred K; Ross, Allen G P.
Afiliação
  • Olveda DU; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
  • Inobaya MT; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia; Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.
  • McManus DP; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Olveda RM; Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.
  • Vinluan ML; Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.
  • Ng SK; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
  • Harn DA; Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.
  • Li Y; QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Hunan Institute for Parasitic Diseases, WHO Collaborating Centre on Schistosomiasis Control in Lake Regions, Yueyang, Hunan, China.
  • Guevarra JR; Research Institute for Tropical Medicine, Department of Health, Muntinlupa, Philippines.
  • Lam AK; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
  • Ross AG; Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia. Electronic address: a.ross@griffith.edu.au.
Int J Infect Dis ; 54: 145-149, 2017 Jan.
Article em En | MEDLINE | ID: mdl-27743969
ABSTRACT

OBJECTIVE:

This study assessed the impact of annual versus biennial praziquantel treatment regimens on the prevalence, intensity of infection, and liver fibrosis dynamics of Asiatic schistosomiasis (caused by Schistosoma japonicum) among individuals residing in 18 endemic barangays in Northern Samar, Philippines.

METHODS:

Five hundred and sixty-five subjects who reported symptoms of gastrointestinal illness and/or were believed to have clinical morbidity based on physical examination were selected for cohort follow-up.

RESULTS:

The mean prevalence of schistosomiasis was 34% and the mean intensity of infection was 123.1 eggs per gram. Moderate to severe hepatic fibrosis (grade II/III) was demonstrated in approximately 25% of the study population. As expected, a greater reduction in both the prevalence and intensity of infection was documented with two treatment rounds versus one. Overall, hepatic fibrosis (grades I-III) regressed in only 24.3% of those who received a single treatment and in only 19.3% of those who received two doses. The prevalence of grade II-III fibrosis at baseline (25.2%) remained unchanged 2 years after treatment.

CONCLUSIONS:

These findings suggest that in order to reverse moderate to severe liver fibrosis due to schistosomiasis and improve clinical outcomes, a higher clinical dosage of praziquantel (i.e., 60-80mg/kg) may be required over an extended duration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Praziquantel / Esquistossomose / Cirrose Hepática Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Animals / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Praziquantel / Esquistossomose / Cirrose Hepática Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Animals / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Asia Idioma: En Ano de publicação: 2017 Tipo de documento: Article